-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $42

Benzinga·07/09/2025 13:14:44
Listen to the news
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $30 to $42.